Markers of endothelial dysfunction, oxidative stress, and inflammation in cerebral small vessel disease

Cerebral Small Vessel Disease

Volumn , Issue , 2011, Pages 192-199

  Pescini, Francesca ^a   Abbate, Rosanna ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923486371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139382694.017     Document Type: Chapter

References (50)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
2. Charlton RA, Morris RG, Nitkunan A, Markus HS. The cognitive profiles of CADASIL and sporadic small vessel disease. Neurology 2006; 66: 1523-1526.
3. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol 2009; 8:643-653.
4. O’sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002; 59:321-326.
5. Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000; 31:1904-1912.
6. Gan R, Sacco RL, Kargman DE, et al. Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology 1997; 48:1204-1211.
7. Bakker SL, de Leeuw FE, de Groot JC, et al. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999; 52: 578-583.
8. Szmitko PE, Wang CH, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation 2003; 108:1917-1923.
9. Blanco M, Rodriguez-Yanez M, Sobrino T, Leira R, Castillo J. Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction. Cerebrovasc Dis 2005; 20(Suppl 2):32-39.
10. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71:804-811.
11. Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012; 78:167-174.
12. Hassan A, Hunt BJ, O’sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126:424-432.
13. Kario K, Matsuo T, Kobayashi H, Asada R, Matsuo M. “Silent” cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lpa levels in elderly Japanese. Arterioscler Thromb Vase Biol 1996; 16:734-741.
14. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, et al. Endothelial activation in lacunar stroke subtypes. Stroke 2010; 41:1617-1622.
15. Fassbender K, Bertsch T, Mielke O, Muhlhauser F, Hennerici M. Adhesion molecules in cerebrovascular diseases. Evidence for an inflammatory endothelial activation in cerebral large-and small-vessel disease. Stroke 1999; 30:1647-1650.
16. De Leeuw FE, de Kleine M, Frijns CJ, et al. Endothelial cell activation is associated with cerebral white matter lesions in patients with cerebrovascular disease. Ann NY Acad Sci 2002; 977:306-314.
17. Markus HS, Hunt B, Palmer K, et al. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005; 36:1410-1414.
18. Khan U, Hassan A, Vallance P, Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-413.
19. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007.
20. Jickling G, Salam A, Mohammad A, et al. Circulating endothelial progenitor cells and age-related white matter changes. Stroke 2009; 40:3191-3196.
21. Chu K, Jung KH, Lee ST, et al. Circulating endothelial progenitor cells as a new marker of endothelial dysfunction or repair in acute stroke. Stroke 2008; 39:1441-1447.
22. Rouhl RP, Mertens AE, van Oostenbrugge RJ, et al. Angiogenic T-cells and putative endothelial progenitor cells in hypertension-related cerebral small vessel disease. Stroke 2012; 43:256-258.
23. Ueda S, Weir CJ, Inglis GC, et al. Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke. JHypertens 1995; 13:1597-1601.
24. Hassan A, Lansbury A, Catto AJ, et al. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunarsyndromes. J Neurol Neurosurg Psychiatry 2002; 72:343-346.
25. Gormley K, Bevan S, Markus HS. Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis 2007; 232: 148-155.
26. Schmidt H, Fazekas F, Kostner GM, van Duijn CM, Schmidt R. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 2001; 32:405-412.
27. Elbaz A, Poirier O, Moulin T, et al. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. The GENIC Investigators. Stroke 2000; 31:1634-1639.
28. Hassan A, Gormley K, O’sullivan M, et al. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke 2004; 35:654-659.
29. Hassan A, Hunt BJ, O’sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127:212-219.
30. Cheng Z, Yang X, Wang H. Hyperhomocysteinemia and endothelial dysfunction. Curr Hypertens Rev 2009; 5:158-165.
31. Schmidt R, Schmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler Thromb Vase Biol 2000; 20: 1811-1816.
32. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996; 27:2043-2047.
33. den Heijer T, Launer LJ, de Groot JC, et al. Serum carotenoids and cerebral white matter lesions: the Rotterdam Scan Study. J Am Geriatr Soc 2001; 49:642-646.
34. Van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112:900-905.
35. Fornage M, Chiang YA, O’Meara ES, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the Cardiovascular Health Study. Stroke 2008; 39:1952-1959.
36. Wada M, Nagasawa H, Kurita K, et al. Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 264: 43-49.
37. Reitz C, Berger K, de Maat MP, et al. CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO study. Stroke 2007; 38:2356-2359.
38. Flex A, Gaetani E, Proia AS, et al. Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer’s disease. J Gerontol A Biol Sci Med Sci 2006; 61:1065-1069.
39. Rouhl RP, Damoiseaux JG, Lodder J, et al. Vascular inflammation in cerebral small vessel disease. Neurobiol Aging 2012; 33:1800-1806.
40. Elkind MS, Luna JM, Coffey CS, et al. The Levels of Inflammatory Markers in the Treatment of Stroke Study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke 2010; 5:117-125.
41. Ruchoux MM, Maurage CA. Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol Appl Neurobiol 1998; 24:60-65.
42. Zhang X, Meng H, Blaivas M, et al. Von Willebrand factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. Transl Stroke Res 2012; 3:138-145.
43. Gobron C, Vahedi K, Vicaut E, et al. Characteristic features of in vivo skin microvascular reactivity in CADASIL. J Cereb Blood Flow Metab 2007; 27:250-257.
44. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J Neurol 2008; 255:1203-1208.
45. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial function of forearm resistance arteries in CADASIL patients. Stroke 2007; 38:2692-2697.
46. Campolo J, De Maria R, Frontali M, et al. Impaired vasoreactivity in mildly disabled CADASIL patients. J Neurol Neurosurg Psychiatry 2012; 83:268-274.
47. Rufa A, Blardi P, De Lalla A, et al. Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy. Cerebrovasc Dis 2008; 26:636-640.
48. Flemming KD, Nguyen TT, Abu-Lebdeh HS, et al. Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Mayo Clin Proc 2001; 76: 1213-1218.
49. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004; 127:2031-2038.
50. Pescini F, Cesari F, Giusti B, et al. Bone marrow-derived progenitor cells in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 2010; 41:218-223.